Royalty Pharma plc - Ordinary Shares - Class A Stock News

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has successfully closed the acquisition of its external manager, RP Management, LLC (“RP Management”). The acquisition received overwhelming support from Royalty Pharma's shareholders, with 99.9% of votes cast in favor of the transaction.

NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May:

NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that shareholders overwhelmingly approved its previously announced external manager acquisition, with 99.9% voting in favor at Royalty Pharma's 2025 Annual General Meeting and Special Meeting of Shareholders (the “Meeting”), marking a key milestone for the company.

Royalty Pharma reported 12% growth in Q1 royalty receipts, driven by Vertex, GSK, and Roche, with adjusted EBITDA reaching $738 million. The company raised its 2025 Portfolio Receipts guidance to $2.97-$3.12 billion, suggesting potential growth opportunities not yet reflected in the current valuation. RPRX repurchased 23 million shares for $723 million and has a $2.3 billion buyback remaining, ...

Royalty Pharma plc (NASDAQ:RPRX ) Q1 2025 Earnings Conference Call May 8, 2025 8:30 AM ET Company Participants George Grofik - Senior Vice President and Head, Investor Relations and Communications Pablo Legorreta - Founder and CEO Marshall Urist - Executive Vice President and Head, Research and Investment Terry Coyne - Executive Vice President and CFO Chris Hite - Executive Vice President and V...

NEW YORK, May 08, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the first quarter of 2025 and raised full year 2025 guidance for Portfolio Receipts.

NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2025 of $0.22 per Class A ordinary share.

NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day.